Abstract
The incidence ofClostridium difficilecolitis has increased during recent years, presumably because of liberal use of broad-spectrum antibiotic regimens. METHODS: A retrospective review to determine patterns ofC. difficilecolitis development, morbidity, and treatment results was undertaken. During an 18-month period, 90 patients were diagnosed withC. difficilecolitis by fecal toxin assays. Patient demographics, symptoms, previously administered antibiotic regimens, diagnostic evaluations, treatment modalities, morbidity, and mortality were identified, entered into a computer data base, and analyzed. RESULTS: The mean age was 58 years; males outnumbered females 1.2∶1. Among 90 patients, 41 (46 percent) developedC. difficilecolitis after surgical procedures. Eighty (89 percent) patients received antibiotic therapy before developingC. difficilecolitis: 35 (44 percent) for documented infections and 45 (56 percent) as empiric or prophylactic therapy. Cephalosporins, penicillins, quinolones, vancomycin, and aminoglycosides were the most frequently administered antibiotic classes prior toC. difficilecolitis diagnosis. Ten (11 percent) patients developedC. difficilecolitis without previous antibiotic therapy. Eighty-two (91 percent) patients presented with diarrhea, while eight (9 percent) had fever only. PrimaryC. difficilecolitis treatment for both groups included vancomycin (66 percent), metronidazole (24 percent), or both drugs (10 percent). Ten (11 percent) patients received no treatment. No patient developed toxic colitis or megacolon. Colonoscopy was performed in four (4 percent) patients; pseudomembranes were identified in one (25 percent) patient. There was oneC. difficilecolitis recurrence after treatment, but noC. difficilecolitis-associated morbidity. Mortality (14 patients, 16 percent) was not related toC. difficilecolitis, but to underlying illness. No difference in patient age, sex, previous antibiotic administration, serum albumin, total days hospitalized, duration ofC. difficilecolitis antibiotic therapy,C. difficilecolitis treatment regimens, or mortality was identified between nonsurgical and surgical patients. The white blood cell count was significantly lower in the nonsurgical group however.Clostridium difficilecolitis developed most commonly after antibiotic administration with symptoms of diarrhea, but did occur without previous antibiotic administration or diarrhea. CONCLUSION: Despite the clinical setting,C. difficilecolitis had no associated morbidity and treatment was highly effective. Mortality was related to underlying medical illness, notC. difficilecolitis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Finney JM. Bulletin of the Johns Hopkins Hospital 1893;4:53.
Larson HE, Parry JV, Price AB, Davies DR, Dolby J, Tyrell DA. Undescribed toxin in pseudomembranous colitis. BMJ 1977;1:1246–8.
Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic associated pseudomembranous colitis, due to toxin producing clostridia. N Engl J Med 1978;298:531–4.
George RH, Symonds JM, Dimock F,et al. Identification ofClostridium difficile as a cause of pseudomembranous colitis. BMJ 1978;1:695–7.
Hall JC, O'Toole E. Intestinal flora in new-born infants with a description of a new pathogenic anaerobe, bacillus difficilis. Am J Dis Child 1955;49:390–402.
Keighley MR. Antibiotic-associated pseudomembranous colitis: pathogenesis and management. Drugs 1980;20:49–56.
Fekety R, Shah AB. Diagnosis and treatment ofClostridium difficile colitis. JAMA 1993;269:71–5.
George WL, Sutler VL, Finegold SM. Toxicity and antimicrobial susceptibility ofClostridium difficile: a cause of antimicrobial agent associated colitis. Curr Microbiol 1978;1:55–8.
Hall J, O'Toole E. Intestinal flora in newborn infant with description of a new pathogenic organism: bacillus difficilis. Am J Dis Child 1935;49:390–402.
Larson HE, Price AB, Honour P, Borriello SP.Clos-tridium difficile and the etiology of pseudomembranous colitis. Lancet 1978;1:1063–6.
Snyder ML. Further studies on bacillus difficilis. J Infect Dis 1937;60:223–31.
Keighley MR, Youngs D, Johnson M, Allan RN, Burdon DW.Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease. Gut 1982;23:410–4.
Lyerly DM, Krivan HC, Wilkins TD.Clostridium difficile: its disease and toxin. Clin Microbiol Rev 1988;1:1–18.
Mogg GA, Keighley MR, Burdon DW,et al. Antibiotic-associated colitis: review of 66 cases, Br J Surg 1979;66:738–42.
Church JM, Fazio VW. A role for colonic stasis in the pathogenesis of disease related toClostridium difficile. Dis Colon Rectum 1986;29:804–9.
Lishman AH, Al Jumaili IJ, Record CO. Spectrum of antibiotic-associated diarrhea. Gut 1981;22:34–7.
Tedesco FJ. Clindamycin-associated colitis: review of the clinical spectrum of 47 cases. Dig Dis Sci 1976;21:26–32.
Sykes PA, Boulier KH, Schofield PF. The microflora of the obstructed bowel. Br J Surg 1976;63:721–5.
Shirrell TG, Egerton JR, Rampling A, Samels J, Walker PD. The etiology and epidemiology of the pig-bel syndrome in man in New Guinea. J Hyg 1966;64:375–96.
Keighley MR, Burdon DW, Arabi Y,et al. Randomized controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhea. BMJ 1978;1:1667–9.
Bartlett JG. Antibiotic-associated diarrhea. Pract Gastroenterol 1992;16:10–7.
Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin antibiotic-associated pseudomembranous colitis. Lancet 1978;2:226–8.
Keighley MR, Burdon DW, Alexander-Williams J,et al. Diarrhoea and pseudomembranous colitis after gastrointestinal operations: a prospective study. Lancet 1978;2:1165–8.
Tedesco FJ, Stanley RJ, Alpers DH. Diagnostic features of clindamycin-associated pseudomembranous colitis. N Engl J Med 1974;290:841–3.
Teasley PG, Gerding DN, Olson MM,et al. Prospective randomized trial of metronidazole versus vancomycin forClostridium difficile-associated diarrhea and colitis. Lancet 1983;2:1043–6.
Cherry RD, Portnoy D, Jabbari M, Daly DS, Kinnear DG, Goresky CA. Metronidazole: an alternate therapy for antibiotic-associated colitis. Gastroenterology 1982;82:849–51.
Kreutzer EW, Milligan FD. Treatment of antibiotic associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J 1978;143:67–71.
Bartlett JG, Tedesco FJ, Shull S, Lowe B, Chang T. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 1980;78:431–4.
Portnoy D, Soneji A, Murray D, Richards CK. Pseudomembranous colitis: multiple relapses after treatment with metronidazole. Can Med Assoc J 1981:124:1603–5.
Chang T, Gorbach SL, Bartlett JG, Saginur R. Bacitracin treatment of antibiotic-associated colitis and diarrhea caused byClostridium difficile toxin. Gastroenterology 1980;78:1584–6.
Rocca JM, Hecker R, Pieterse AS, Rich GE, Rowland R.Clostridium difficile colitis. Aust N Z J Med 1984;14:606–10.
Rosenberg JM, Walker M, Welch JP, Mullany L.Clostridium difficile colitis in surgical patients. Am J Surg 1984;147:486–91.
Gerding DN, Olson MM, Peterson LR,et al.Clostridium difficile-associated diarrhea and colitis in adults. Arch Intern Med 1986;146:95–100.
Talbot RW, Walker RC, Beart RW. Changing epidemiology, diagnosis, and treatment ofClostridium difficile toxin-associated colitis. Br J Surg 1986;73:457–60.
Clarke HJ, Jinnah RH, Byank RP, Cox QGN.Clostridium difficile infection in orthopaedic patients. J Bone Joint Surg [Am] 1990;72:1056–59.
Author information
Authors and Affiliations
Additional information
Read at the meeting of The American Society of Colon and Rectal Surgery, Chicago, Illinois, May 2 to 7, 1993.
About this article
Cite this article
Marts, B.C., Longo, W.E., Vernava, A.M. et al. Patterns and prognosis ofClostridium difficile colitis. Dis Colon Rectum 37, 837–845 (1994). https://doi.org/10.1007/BF02050152
Issue Date:
DOI: https://doi.org/10.1007/BF02050152